AlHabeeb Waleed, Hayajneh Ahmad
Cardiac Sciences Department, King Saud University, Riyadh, Saudi Arabia.
King Fahad Cardiac Center, King Saud Saud University Medical City, Riyadh, Saudi Arabia.
Int J Gen Med. 2021 May 24;14:2041-2045. doi: 10.2147/IJGM.S310309. eCollection 2021.
The aim of this study was to show whether blocking the deleterious effects of neurohormonal activation from furosemide by the use of ACEI/ARBs, or the improvement of renal perfusion by using these drugs allows better diuresis and renal function preservation.
This is a prospective, randomized study in which patients with chronic heart failure were included. Patients admitted for ACEI/ARBs maintenance with acute decompensated HF were added in the study. The patients were divided into two groups: group 1 had ACEI/ARBs continued during admission and group 2 had stopped taking them. Patients with acute heart failure were provided with angiotensin II receptor blockers. Therefore, the present study aims to differentiate between the uses of ACEI/ARBs blocking the deleterious effects of neurohormonal activation or the improvement of renal perfusion by holding these drugs to allow better diuresis and renal function preservation in a young population.
The results showed that the mean age of 32 patients of group 1 was 58±15.3 and for group 2 56±15.6. On day of analysis, BP was 113/65±11.9/6.5 and 108/66.9±14.1/9.8, weight was 68.4±19.8 kg and 73.7±20.2 kg, net volume balance of urine output was 2810.3±1011.8 mL and 3941.7±2849.7 mL, and length of stay was 11.75±6 and 7.9±3.7 days for groups 1 and 2, respectively. There was no significant difference in SBP (=0.2926), DBP (=0.7369), weight (=0.4798), glomerular filtration rate (GFR) (=0.7), and volume balance (=0.166). However, there was statistically significant difference in length of hospital stay (=0.0392).
The study concluded that continuing ACEI/ARBs or holding them during IV diuresis had no difference in the effect on kidney function or diuresis. Length of stay appears to be shorter for those who held their ACEI/ARBs.
本研究旨在表明,使用血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂(ACEI/ARBs)阻断速尿引起的神经激素激活的有害影响,或使用这些药物改善肾灌注是否能实现更好的利尿效果并保护肾功能。
这是一项前瞻性随机研究,纳入了慢性心力衰竭患者。因急性失代偿性心力衰竭而接受ACEI/ARBs维持治疗的入院患者也被纳入该研究。患者被分为两组:第1组在入院期间继续使用ACEI/ARBs,第2组则停止服用。急性心力衰竭患者使用血管紧张素Ⅱ受体阻滞剂。因此,本研究旨在区分使用ACEI/ARBs是通过阻断神经激素激活的有害影响,还是通过停用这些药物改善肾灌注,从而在年轻人群中实现更好的利尿效果并保护肾功能。
结果显示,第1组32例患者的平均年龄为58±15.3岁,第2组为56±15.6岁。在分析当天,第1组的血压为113/65±11.9/6.5,第2组为108/66.9±14.1/9.8;体重分别为68.4±19.8千克和73.7±20.2千克;尿量净平衡分别为2810.3±1011.8毫升和3941.7±2849.7毫升;住院时间第1组为11.75±6天,第2组为7.9±3.7天。收缩压(=0.2926)、舒张压(=0.7369)、体重(=0.4798)、肾小球滤过率(GFR)(=0.7)和容量平衡(=0.166)方面无显著差异。然而,住院时间存在统计学显著差异(=0.0392)。
该研究得出结论,在静脉利尿期间继续使用或停用ACEI/ARBs对肾功能或利尿效果无差异。停用ACEI/ARBs的患者住院时间似乎更短。